Literature DB >> 3088645

Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET).

P Hartvig, S A Eckernäs, L Lindström, B Ekblom, U Bondesson, H Lundqvist, C Halldin, K Någren, B Långström.   

Abstract

By means of positron emission tomography the uptake and kinetics of N-(methyl-11C)clozapine in different brain regions have been studied in Rhesus monkeys. 11C-clozapine rapidly entered the brain and maximum radioactive uptake was seen 5-12 min after administration. Highest uptake was measured in the striatum. Other regions with an uptake higher than in the cerebellum were thalamus and mesencephalon. The radioactivity from different brain regions decreased with an elimination half-life of about 5 h and parallelled the plasma kinetics of unlabelled clozapine. The striatum/cerebellum ratio of 11C-clozapine-derived radioactivity remained constant during the period studied and did not change after pretreatment with atropine. In contrast, the striatum/cerebellum ratio was somewhat lower after pretreatment with N-methylspiperone (NMSP), indicating competition for the same binding sites in the striatum. After pretreatment with increasing doses of clozapine, a dose-dependent protection of binding sites in the striatum for 11C-NMSP was seen. It is concluded that clozapine is more loosely bound to dopamine receptors in the striatum than N-methylspiperone and that the kinetics of clozapine in the brain parallel that in the plasma. The binding properties of clozapine within the brain may explain some of the clinical properties of the drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3088645     DOI: 10.1007/bf00310638

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

2.  Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain.

Authors:  D F Wong; H N Wagner; R F Dannals; J M Links; J J Frost; H T Ravert; A A Wilson; A E Rosenbaum; A Gjedde; K H Douglass
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

3.  Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.

Authors:  A C Sayers; H R Bürki; W Ruch; H Asper
Journal:  Psychopharmacologia       Date:  1975

4.  Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal.

Authors:  B Ekblom; K Eriksson; L H Lindström
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Kinetics of 11C-labeled opiates in the brain of rhesus monkeys.

Authors:  P Hartvig; K Bergström; B Lindberg; P O Lundberg; H Lundqvist; B Långström; H Svärd; A Rane
Journal:  J Pharmacol Exp Ther       Date:  1984-07       Impact factor: 4.030

6.  Imaging dopamine receptors in the human brain by positron tomography.

Authors:  H N Wagner; H D Burns; R F Dannals; D F Wong; B Langstrom; T Duelfer; J J Frost; H T Ravert; J M Links; S B Rosenbloom; S E Lukas; A V Kramer; M J Kuhar
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

7.  Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey.

Authors:  E Ehrin; L Farde; T de Paulis; L Eriksson; T Greitz; P Johnström; J E Litton; J L Nilsson; G Sedvall; S Stone-Elander
Journal:  Int J Appl Radiat Isot       Date:  1985-04

8.  Peripheral and central muscarinic receptor affinity of psychotropic drugs.

Authors:  B Fjalland; A V Christensen; J Hyttel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-12       Impact factor: 3.000

9.  (3-N-[11C]methyl)spiperone, a ligand binding to dopamine receptors: radiochemical synthesis and biodistribution studies in mice.

Authors:  H D Burns; R F Dannals; B Langström; H T Ravert; S E Zemyan; T Duelfer; D F Wong; J J Frost; M J Kuhar; H N Wagner
Journal:  J Nucl Med       Date:  1984-11       Impact factor: 10.057

10.  Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years.

Authors:  U Juul Povlsen; U Noring; R Fog; J Gerlach
Journal:  Acta Psychiatr Scand       Date:  1985-02       Impact factor: 6.392

View more
  9 in total

1.  Supersensitivity and clozapine withdrawal.

Authors:  K Eklund
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Clinical pharmacokinetics of clozapine in chronic schizophrenic patients.

Authors:  Y F Cheng; T Lundberg; U Bondesson; L Lindström; J Gabrielsson
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Tardive psychosis: does it exist?

Authors:  T Palmstierna; B Wistedt
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 4.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

5.  Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine.

Authors:  E R Korpi; G Wong; H Lüddens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

6.  High-dose Clozapine Withdrawal: A Case Report and Timeline of a Single Potential Withdrawal Seizure.

Authors:  Megan K Skelly; Tammie Lee Demler; Claudia Lee
Journal:  Innov Clin Neurosci       Date:  2019-07-01

7.  Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers.

Authors:  T Lundberg; L H Lindström; P Hartvig; S A Eckernâs; B Ekblom; H Lundqvist; K J Fasth; P Gullberg; B Långström
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  18F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography.

Authors:  Feng Hu; Patrick J Morris; Jordi Bonaventura; Hong Fan; William B Mathews; Daniel P Holt; Sherry Lam; Matthew Boehm; Robert F Dannals; Martin G Pomper; Michael Michaelides; Andrew G Horti
Journal:  Eur J Med Chem       Date:  2020-11-25       Impact factor: 6.514

9.  PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation.

Authors:  Yuji Nagai; Erika Kikuchi; Walter Lerchner; Ken-Ichi Inoue; Bin Ji; Mark A G Eldridge; Hiroyuki Kaneko; Yasuyuki Kimura; Arata Oh-Nishi; Yukiko Hori; Yoko Kato; Toshiyuki Hirabayashi; Atsushi Fujimoto; Katsushi Kumata; Ming-Rong Zhang; Ichio Aoki; Tetsuya Suhara; Makoto Higuchi; Masahiko Takada; Barry J Richmond; Takafumi Minamimoto
Journal:  Nat Commun       Date:  2016-12-06       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.